BRPI0820701A2 - Composto de carboxamida e seu uso como agonistas do receptor de quimiocina - Google Patents

Composto de carboxamida e seu uso como agonistas do receptor de quimiocina

Info

Publication number
BRPI0820701A2
BRPI0820701A2 BRPI0820701-1A BRPI0820701A BRPI0820701A2 BR PI0820701 A2 BRPI0820701 A2 BR PI0820701A2 BR PI0820701 A BRPI0820701 A BR PI0820701A BR PI0820701 A2 BRPI0820701 A2 BR PI0820701A2
Authority
BR
Brazil
Prior art keywords
receptor agonists
chemokine receptor
carboxamide compound
carboxamide
compound
Prior art date
Application number
BRPI0820701-1A
Other languages
English (en)
Inventor
Efrat Ben-Zeev
Dongli Chen
Merav Fichman
Shomir Ghosh
Steffi Koerner
Jian Lin
Yael Marantz
Rosa Melendez
Pradyumma Mohanty
Sharon Shacham
Zhaoda Zhang
Original Assignee
Cytopathfinder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytopathfinder Inc filed Critical Cytopathfinder Inc
Publication of BRPI0820701A2 publication Critical patent/BRPI0820701A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
BRPI0820701-1A 2007-12-11 2008-12-11 Composto de carboxamida e seu uso como agonistas do receptor de quimiocina BRPI0820701A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1281907P 2007-12-11 2007-12-11
US3667508P 2008-03-14 2008-03-14
PCT/US2008/086388 WO2009076512A1 (en) 2007-12-11 2008-12-11 Carboxamidξ compounds and their use as chemokine receptor agonists

Publications (1)

Publication Number Publication Date
BRPI0820701A2 true BRPI0820701A2 (pt) 2015-06-16

Family

ID=40352365

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820701-1A BRPI0820701A2 (pt) 2007-12-11 2008-12-11 Composto de carboxamida e seu uso como agonistas do receptor de quimiocina

Country Status (10)

Country Link
US (1) US8569282B2 (pt)
EP (1) EP2280766A1 (pt)
JP (1) JP2011506466A (pt)
KR (1) KR20100102646A (pt)
CN (1) CN101925383A (pt)
AU (1) AU2008335135A1 (pt)
BR (1) BRPI0820701A2 (pt)
CA (1) CA2708364A1 (pt)
RU (1) RU2010128543A (pt)
WO (1) WO2009076512A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685266C (en) 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
TW201105649A (en) * 2009-04-16 2011-02-16 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of CCR2
EP2419419B1 (en) * 2009-04-17 2014-12-03 Janssen Pharmaceutica NV 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
CN102459226B (zh) * 2009-04-17 2014-09-17 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-杂原子连接的-环己烷拮抗剂
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
GB201115633D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of efavirenz
JO3407B1 (ar) * 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
KR102867210B1 (ko) * 2021-10-01 2025-10-14 신테라, 인크. 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
AU2023259236B2 (en) 2022-04-28 2025-01-09 Xinthera, Inc. Tricyclic parp1 inhibitors and uses thereof
WO2025055965A1 (zh) * 2023-09-13 2025-03-20 中国药科大学 氮杂环丁烷衍生物、其制备方法及其医药用途
WO2025131049A1 (en) * 2023-12-21 2025-06-26 Ignis Therapeutics (Suzhou) Limited Dihydro-pyrrolo-pyridine derivatives and uses thereof

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3383281A (en) 1961-09-22 1968-05-14 Merck & Co Inc Method for binding bile acids in vivo
SE353319B (pt) 1964-08-15 1973-01-29 Sumitomo Chemical Co
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4058552A (en) 1969-01-31 1977-11-15 Orchimed Sa Esters of p-carbonylphenoxy-isobutyric acids
US3803237A (en) 1969-11-03 1974-04-09 Upjohn Co Reaction products of polyethylenepolyamines and chlorohydrins or epoxy containing compounds
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
DE2708913A1 (de) 1976-03-04 1977-09-08 Hoechst Ag Benzoylpiperidyalkyl-indole und verwandte verbindungen
FR2350341A1 (fr) 1976-05-07 1977-12-02 Synthelabo Nouveaux derives de piperidine et leur methode de preparation
GB2021108B (en) 1978-05-18 1982-07-21 Pfizer Ltd 6,7 - di - 4 - amino - 2 - quinazolines
DK159079A (da) 1978-05-18 1979-11-19 Pfizer Fremgangsmaade til fremstilling af derivater af 4-amino-2-piperidinoquinazolin eller syreadditionssalte deraf
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4452813A (en) 1981-05-22 1984-06-05 Taiho Pharmaceutical Company Limited Sulfonate derivatives, process for preparing same and antilipemic compositions containing the derivative
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US4716175A (en) 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
EP0306375A1 (fr) 1987-08-07 1989-03-08 Synthelabo Dérivés de[(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique
WO1990005132A1 (fr) 1988-11-11 1990-05-17 Banyu Pharmaceutical Co., Ltd. Derives d'allylamine substitues, procede de preparation et utilisation
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5391571A (en) 1989-11-15 1995-02-21 American Home Products Corporation Cholesterol ester hydrolase inhibitors
SE8904298D0 (sv) 1989-12-21 1989-12-21 Astra Ab New compounds
US5102915A (en) 1990-03-22 1992-04-07 Merrell Dow Pharmaceuticals Inc. Cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5051534A (en) 1990-03-22 1991-09-24 Merrell Dow Pharmaceuticals Inc. Novel cyclopropyl squalene derivatives and their use as inhibitors of cholesterol synthesis
US5011859A (en) 1990-03-30 1991-04-30 Merrell Dow Pharmaceuticals Inc. Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
US5064864A (en) 1990-03-30 1991-11-12 Merrell Dow Pharmaceuticals Inc. Di- and tetra-fluoro analogs of squalene as inhibitors of squalene epoxidase
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
ZA915659B (en) 1990-07-25 1992-05-27 Merrell Dow Pharma Novel piperidyl ethers and thioethers as inhibitors of cholesterol biosynthesis
US5026554A (en) 1990-09-13 1991-06-25 Merck & Co., Inc. Method of inhibiting fungal growth using squalene synthetase inhibitors
US5084461A (en) 1991-03-27 1992-01-28 Merrell Dow Pharmaceuticals Inc. Azadecalin amides and thioamides as inhibitors of cholesterol biosynthesis
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
CA2098167C (en) 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
US5364867A (en) 1992-11-30 1994-11-15 Sterling Winthrop Inc. 4-phenylpiperdine agents for treating cns disorders
US5635510A (en) 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
US5824690A (en) 1993-05-06 1998-10-20 Hoechst Marion Roussel Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
TW381025B (en) 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
SE9400447D0 (sv) 1994-02-11 1994-02-11 Astra Ab New compounds
US5576313A (en) 1994-08-29 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
MX9703518A (es) 1994-11-16 1997-08-30 Synaptic Pharma Corp Dihidropirimidinas y usos de las mismas.
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US5688960A (en) 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
DK0832069T3 (da) 1995-06-07 2003-04-22 Pfizer Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
FR2735129B1 (fr) 1995-06-07 1997-07-11 Adir Nouveaux derives de l'indole, de l'indazole et du benzisoxazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EA001539B1 (ru) 1996-11-27 2001-04-23 Пфайзер Инк. Амиды, ингибирующие секрецию аполипопротеина в (аро в) и/или микросомного протеина переноса триглицеридов (мтр)
US5977139A (en) 1996-12-15 1999-11-02 Hoechst Marion Roussel, Inc. Carboxysubstituted cyclic carboxamide derivatives
US5861417A (en) 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
JP2001513369A (ja) 1997-08-11 2001-09-04 アラーガン・セイルズ・インコーポレイテッド 改善された生物適合性を有する無菌の生物侵食性の移植デバイスおよび方法
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6316445B1 (en) 1998-05-15 2001-11-13 Aventis Pharmaceuticals Inc. Carboxy substituted acylic carboxamide derivatives
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6133291A (en) 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
DE60009287T2 (de) 1999-06-03 2005-02-17 Yamanouchi Pharmaceutical Co., Ltd. Neuartige isoquinolin-derivate oder salze davon
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
ATE250604T1 (de) 1999-10-27 2003-10-15 Millennium Pharm Inc Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
JP2004506687A (ja) 2000-08-23 2004-03-04 メルク　エンド　カムパニー　インコーポレーテッド メラノコルチン受容体作働薬としての置換ピペリジン類
US6620438B2 (en) 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020137764A1 (en) 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
EP1339438B1 (en) 2000-11-29 2005-10-19 Allergan Inc. Preventing transplant rejection in the eye
MXPA03008356A (es) 2001-03-13 2003-12-11 Schering Corp Compuestos del tipo no imidazol como antagonistas de histamina h3.
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
BR0213611A (pt) 2001-10-02 2005-12-20 Acadia Pharm Inc Composto, composição farmacêutica, seus usos, método para aumentar a atividade de um receptor colinérgico, métodos para tratamento ou prevenção de distúrbio mental, dor, pressão intraocular aumentada e progressão ou formação de placas amilóides
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
US7220735B2 (en) 2002-04-18 2007-05-22 Schering Corporation Benzimidazolone histamine H3 antagonists
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7230008B2 (en) 2002-04-29 2007-06-12 Merck & Co, Inc. Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
WO2004014377A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
WO2004024720A1 (en) 2002-09-11 2004-03-25 Merck & Co., Inc. Piperazine urea derivatives as melanocortin-4 receptor agonists
WO2004033427A1 (en) 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CN1826334A (zh) * 2003-03-18 2006-08-30 麦克公司 趋化因子受体活性的四氢吡喃基环戊基杂环酰胺调节剂
EP1468999A1 (en) 2003-03-20 2004-10-20 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
CN1764458A (zh) 2003-03-26 2006-04-26 麦克公司 作为黑皮质素－4受体激动剂的双环哌啶衍生物
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2004275488A1 (en) 2003-09-26 2005-04-07 Actelion Pharmaceuticals Ltd Pyridine derivatives and use thereof as urotensin II antagonists
GB0325745D0 (en) 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
JP2007522219A (ja) * 2004-02-12 2007-08-09 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性のアミノ複素環式調節物質
BRPI0509660A (pt) 2004-04-09 2007-10-09 Millennium Pharm Inc compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
CA2565599C (en) 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2005121090A1 (en) 2004-06-02 2005-12-22 Abbott Laboratories Substituted piperidines that have antiangiogenic activity
EP1778646A1 (en) 2004-08-11 2007-05-02 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
CN101065374A (zh) 2004-09-28 2007-10-31 詹森药业有限公司 取代的二哌啶化学引诱物细胞因子受体2拮抗剂
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
FR2876692B1 (fr) * 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MX2007006214A (es) 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
ES2434467T3 (es) 2005-05-13 2013-12-16 Lexicon Pharmaceuticals, Inc. Compuestos multicíclicos y métodos para su uso
US7425633B2 (en) * 2005-08-26 2008-09-16 National Health Research Institutes Pyrrolidine compounds
WO2007053499A2 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
AR063275A1 (es) 2006-10-12 2009-01-14 Epix Delaware Inc Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2.
US20100184749A1 (en) 2006-10-12 2010-07-22 EPIX Delaware ,Inc. Benzothiadiazine compounds and their use
WO2009076404A1 (en) 2007-12-10 2009-06-18 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
WO2010129843A1 (en) 2009-05-08 2010-11-11 Cytopathfinder, Inc. Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders

Also Published As

Publication number Publication date
AU2008335135A1 (en) 2009-06-18
US8569282B2 (en) 2013-10-29
WO2009076512A1 (en) 2009-06-18
EP2280766A1 (en) 2011-02-09
RU2010128543A (ru) 2012-01-20
JP2011506466A (ja) 2011-03-03
CN101925383A (zh) 2010-12-22
US20100324035A1 (en) 2010-12-23
CA2708364A1 (en) 2009-06-18
KR20100102646A (ko) 2010-09-24

Similar Documents

Publication Publication Date Title
BRPI0820701A2 (pt) Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
BRPI0820447A2 (pt) Agonistas do receptor de glicocorticóides
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
BR112012002349A2 (pt) composto,e, uso do mesmo
BRPI0815349A2 (pt) 6-amino-5-cloro-4-pirimidinacarboxilatos substituídos com 2-(2-fluorofeni-la) e seu uso como herbicidas
PL2513093T3 (pl) Nowi antagoniści receptora CCR2 i ich zastosowanie
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
PT2547679E (pt) Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
DK2421849T3 (da) Diamidforbindelser med muscarinreceptorantagonist- og beta2-adrenoreceptoragonist-virkning
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0920237A2 (pt) agonistas do receptor aril gpr120 e suas respectivas utilizações
CR10849A (es) Derivados de benzamida como agonistas del receptor ep4
BRPI0720866A2 (pt) Derivados de oxindol substituídos e seu uso como ligandos de receptor de vasopressina
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
ES2385606T8 (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI0918128A2 (pt) derivados de heterozril amida e seu uso como ativadores de glicocinase
BRPI1007494A2 (pt) composto e uso do mesmo
BRPI0913885A2 (pt) Tiadiazoliloxifenilamidinas e seus uso como fungicidas
BRPI0814231A2 (pt) Derivados de pleuromutilina e seu uso como antimicrobianos
BRPI0718494A2 (pt) Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BR112013004662A2 (pt) agonistas de receptores de neurotrofina e o uso destes como medicamentos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.